StockData
Sanofi logo

Sanofi (SNY) stock

SNYNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SNYNF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 17, 2026Score 6/30
$47.12−0.41 (-0.86%)

Close on Nov 18, 2026Market cap $114.92BP/E 13.4Yield –

Earnings

Sanofi's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2023
€11.96B
Business EPS, Q2 FY2023
2.55 EUR
Latest guidance
Issued
Oct 27, 2023 · 3 items

Quarterly results

Revenue and earnings per share from each of Sanofi's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2025ended Jun 30, 2025Oct 27, 2025before the open––––Release
Q2 FY2023ended Jun 30, 2023Oct 27, 2023during market hours€11.96B–2.01 EUR2.55 EURRelease

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Sanofi's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
expected one-off COVID vaccine revenuesQ4 FY2023400–NewOct 27, 2023
currency impact on 2023 business EPSnon-GAAPFY2023-7% – -6%–NewOct 27, 2023
effective tax ratenon-GAAPFY202319%–NewOct 27, 2023

Guidance history

Every forecast Sanofi put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 27, 2023currency impact on 2023 business EPSFY2023-7% – -6%New
Oct 27, 2023effective tax rateFY202319%New
Oct 27, 2023expected one-off COVID vaccine revenuesQ4 FY2023400New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers Sanofi reports itself, taken from its earnings releases

MeasureQ2 FY2023
Business operating income€4.03B
Business net income€3.20B
Business EPS2.55 EUR
Free cash flow€1.85B

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases Sanofi filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?